Target therapies are mainly based on the use of small molecule inhibitors for v-raf murine sarcoma viral oncogene homolog B1 (BRAF)- and/or mitogen-activated protein kinase (MEK)-mutated melanomas, which specifically inhibit the most common oncogenic driver mutation responsible for melanoma cell proliferation and survival [7,8,9]. Here, WNK2 is linked to melanoma.